Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Dec 2024 value amounting to -$991,359.

  • Cumberland Pharmaceuticals' Change in Accured Expenses fell 45.65% to $684,224 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year increase of 58.27%. This contributed to the annual value of -$991,359 for FY2024, which is 29.46% up from last year.
  • According to the latest figures from FY2024, Cumberland Pharmaceuticals' Change in Accured Expenses is -$991,359, which was up 29.46% from -$1.4 million recorded in FY2023.
  • Over the past 5 years, Cumberland Pharmaceuticals' Change in Accured Expenses peaked at $14.5 million during FY2022, and registered a low of -$1.4 million during FY2023.
  • Its 3-year average for Change in Accured Expenses is $4.0 million, with a median of -$991,359 in 2024.
  • In the last 5 years, Cumberland Pharmaceuticals' Change in Accured Expenses crashed by 111.53% in 2021 and then skyrocketed by 2,018.72% in 2022.
  • Cumberland Pharmaceuticals' Change in Accured Expenses (Yearly) stood at $6.6 million in 2020, then slumped by 111.53% to -$757,591 in 2021, then surged by 2,018.72% to $14.5 million in 2022, then tumbled by 109.67% to -$1.4 million in 2023, then rose by 29.46% to -$991,359 in 2024.